Contineum Therapeutics (CTNM) Cash from Investing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $4.9 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 65.04% year-over-year to $4.9 million; the TTM figure through Jun 2026 stood at -$67.0 million (down 521.67% YoY), while the FY2025 annual figure was -$3.7 million, up 94.68% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at $4.9 million, up from -$39.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $14.9 million in Q3 2025, with the low at -$47.5 million in Q4 2025.
• The 4-year median for Cash from Investing Activities is -$2.3 million (2024), against an average of -$12.4 million.
• Peak annual rise in Cash from Investing Activities reached 149.5% in 2025, while the deepest fall reached 405.46% in 2025.
• Contineum Therapeutics' Cash from Investing Activities stood at $9.0 million in 2023, then tumbled by 203.96% to -$9.4 million in 2024, then slumped by 405.46% to -$47.5 million in 2025, then soared by 110.23% to $4.9 million in 2026.
• Business Quant data shows CTNM's Cash from Investing Activities at $4.9 million in Q2 2026, -$39.3 million in Q1 2026, and -$47.5 million in Q4 2025.